Story · Medicine & Biotech
Pfizer leaps into ‘in vivo’ CAR-T with latest China deal
1 outlet · first reported by BioPharma Dive on
The potentially $2.6 billion collaboration puts Pfizer into a competitive race to treat autoimmune conditions by reprogramming cells inside the body. (BioPharma Dive)
Coverage, in order
-
Pfizer leaps into ‘in vivo’ CAR-T with latest China dealThe potentially $2.6 billion collaboration puts Pfizer into a competitive race to treat autoimmune conditions by reprogramming cells inside the body.
Alivewire groups outlets reporting the same story. Each headline links to the outlet that wrote it; nothing is republished here.